{"page":{"totalFilteredElements":381},"studies":[{"active":true,"description":"Register und Biobank\nseltene maligne Tumoren der Schilddr&#252;se und Nebenschilddr&#252;sen","eudractNumber":null,"id":1811,"indications":[{"id":"sch","name":"Schilddrüsenkarzinom"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2013-10-04T09:56:39+02:00","shortTitle":"Register und Biobank für seltene maligne Tumoren der Schilddrüse und Nebenschilddrüsen","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Mammakarzinom des Mannes - Eine prospektive Registerstudie der Universit&#228;tsfrauenklinik Magdeburg in Zusammenarbeit mit der GBG (German Breast Group) zur Diagnostik und Therapie des Mammakarzinoms des Mannes<div><br /></div><div>DRKS00009536</div>","eudractNumber":null,"id":1491,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2009-04-01T14:01:18+02:00","shortTitle":"Registerstudie Mammakarzinom des Mannes","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<div><div><div>Male breast cancer - A prospective registry study of the University Women's Hospital Magdeburg in cooperation with the GBG (German Breast Group) on the diagnosis and treatment of male breast cancer</div><div><br /></div><div>DRKS00009536</div></div><div><br /></div></div>","eudractNumber":null,"id":6191,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2009-09-08T13:54:40+02:00","shortTitle":"Registerstudie Mammakarzinom des Mannes","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Tumor-Treating-Fields (Optune&#8482;) in der Routineanwendung bei der\nPrim&#228;rtherapie des Glioblastoms: multizentrische Registerstudie zur Erfassung\nder Therapieeffektivit&#228;t und des Rezidivmusters&#8220;","eudractNumber":null,"id":6513,"indications":[{"id":"zns","name":"Hirntumore (ZNS Tumore)"},{"id":"zns1","name":"Astrozytäre Gliome (Astrozytom, Glioblastom)"},{"id":"zns2","name":"Meningeom"},{"id":"zns3","name":"Akustikusneurinom (Vestibularis-Schwannom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2020-11-23T11:11:19+01:00","shortTitle":"Registerstudie Optune","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"PROVIDENCE&#160;- Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan (PROVIDENCE)","eudractNumber":null,"id":10995,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"HER2/neu","id":"mt_19"}],"nctNumber":"NCT05573893","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2022-09-18T11:55:19+02:00","shortTitle":"Registerstudie PROVIDENCE","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Digital Monitoring with Patient-reported outcomes in cancer care: A randomized controlled trial","eudractNumber":null,"id":11846,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06867705","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-01-12T11:48:28+01:00","shortTitle":"Resilience- RC-102","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Retentionsrate von Acalabrutinib in einem nicht-interventionellen Setting","eudractNumber":null,"id":9260,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05645172","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2023-01-05T09:26:40+01:00","shortTitle":"Retain","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Clinical Research Platform For Molecular Testing, Treatment, Quality Of Life And Outcome Of Patients With Esophageal, Gastric Or Gastroesophageal Junction Cancer Requiring Palliative Systemic Therapy (SAPHIR)<br />","eudractNumber":null,"id":5701,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio1","name":"Karzinom der Speiseröhre (Oesophaguskarzinom, inkl. gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04290806","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2019-12-19T10:45:37+01:00","shortTitle":"SAPHIR","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<p>Prospective Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcome Data in Ovarian Cancer Patients Eligible for First-line Platinum-based Chemotherapy and Intended for BRCA/HRD Testing </p>","eudractNumber":null,"id":7907,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"BRCA (BReast CAncer)","id":"mt_204"}],"nctNumber":"NCT04830709","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2021-12-13T13:30:32+01:00","shortTitle":"SCOUT-1","therapeutical":false,"therapyLines":[]},{"active":true,"description":"A non-interventional study of selinexor (Nexpovio) in combination with bortezomib and dexamethasone (SVd) in patients with relapsed or refractory multiple myeloma (R/RMM) - SEATTLE -","eudractNumber":null,"id":11163,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-02-01T14:17:05+01:00","shortTitle":"SEATTLE","therapeutical":false,"therapyLines":[{"id":"tl_4","name":"> Drittlinie"}]}]}